Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster Dose of GBS-NN/NN2 Vaccine in Healthy Women
NCT05005247Phase 1Completed
- Sponsor
- MinervaX
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GBS-NN/NN2 vaccine in Group B streptococcal infection (GBS), sponsored by MinervaX. Primary endpoint: Treatment Emergent Adverse Events at 12 weeks. Started Aug 2021; status: completed.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Group B streptococcal infection (GBS)
Beyond the preview
Go deeper on NCT05005247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005247.